Come dive into one of the curiously delightful conversations overheard at National Geographic’s headquarters, as we follow explorers, photographers, and scientists to the edges of our big, weird, beautiful world. Hosted by Peter Gwin and Amy Briggs.
…
continue reading
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Ovarian Cancer | Breakfast with the Investigators: Exploring the Role of PARP Inhibition in the Management of Ovarian Cancer
QUICKTIME•Episode home
Manage episode 237849597 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Jonathan A Ledermann and Drs Joyce F Liu and David M O’Malley.
- Introduction
- Program overview: Dr Love (00:00)
- Genetic Drivers of Ovarian Cancer Development and Current Testing Algorithms; PARP Inhibitors in the Management of Newly Diagnosed Disease (1:19)
- Case (Dr Liu): A woman in her early 60s who presented with gangrene of the fingers as a result of paraneoplastic syndrome and was found to have high-grade serous ovarian cancer (1:30)
- Case (Prof Ledermann): A woman in her early 70s with advanced ovarian cancer and a germline BRCA1 mutation who is a Jehovah’s Witness did not undergo debulking survey but enrolled on the SOLO-1 trial of maintenance olaparib (16:00)
- Case (Dr O’Malley): A woman in her 60s with Stage IIIC high-grade serous ovarian cancer with a somatic BRCA2 mutation who underwent optimal debulking surgery and received IP chemotherapy and maintenance olaparib (31:53)
- Role of PARP Inhibition in the Management of Relapsed Ovarian Cancer (35:09)
- Case (Prof Ledermann): A nurse in her late 50s with BRCA wild-type, platinum-sensitive recurrent ovarian cancer who received niraparib maintenance therapy (43:03)
- Case (Dr Liu): A woman in her early 60s with multiply relapsed ovarian cancer and a germline BRCA2 mutation who received rucaparib monotherapy (49:46)
- Investigational Applications of Approved PARP Inhibitors; Other PARP Inhibitors in Clinical Development (57:09)
1325 episodes
QUICKTIME•Episode home
Manage episode 237849597 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Jonathan A Ledermann and Drs Joyce F Liu and David M O’Malley.
- Introduction
- Program overview: Dr Love (00:00)
- Genetic Drivers of Ovarian Cancer Development and Current Testing Algorithms; PARP Inhibitors in the Management of Newly Diagnosed Disease (1:19)
- Case (Dr Liu): A woman in her early 60s who presented with gangrene of the fingers as a result of paraneoplastic syndrome and was found to have high-grade serous ovarian cancer (1:30)
- Case (Prof Ledermann): A woman in her early 70s with advanced ovarian cancer and a germline BRCA1 mutation who is a Jehovah’s Witness did not undergo debulking survey but enrolled on the SOLO-1 trial of maintenance olaparib (16:00)
- Case (Dr O’Malley): A woman in her 60s with Stage IIIC high-grade serous ovarian cancer with a somatic BRCA2 mutation who underwent optimal debulking surgery and received IP chemotherapy and maintenance olaparib (31:53)
- Role of PARP Inhibition in the Management of Relapsed Ovarian Cancer (35:09)
- Case (Prof Ledermann): A nurse in her late 50s with BRCA wild-type, platinum-sensitive recurrent ovarian cancer who received niraparib maintenance therapy (43:03)
- Case (Dr Liu): A woman in her early 60s with multiply relapsed ovarian cancer and a germline BRCA2 mutation who received rucaparib monotherapy (49:46)
- Investigational Applications of Approved PARP Inhibitors; Other PARP Inhibitors in Clinical Development (57:09)
1325 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.